NCT01346930View on ClinicalTrials.gov

Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Macitentan

10 mg, tablet, once daily

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY